Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Dipeptidyl peptidase 4 inhibitors reduce costs in T2DM management

    • 1 Accesses

    This is a preview of subscription content, log in to check access.

    Notes

    1. 1.

      The study was sponsored by Merck, Sharp and Dohme (MSD) France.

    Reference

    1. Emery C, et al. Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database. Diabetes Therapy : Jan 2020. Available from: URL: http://doi.org/10.1007/s13300-020-00760-x

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Dipeptidyl peptidase 4 inhibitors reduce costs in T2DM management. PharmacoEcon Outcomes News 846, 12 (2020). https://doi.org/10.1007/s40274-020-6551-9

    Download citation